Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Rating of “Hold” by Analysts

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has earned a consensus rating of “Hold” from the eight ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $12.00.

Several analysts recently issued reports on JSPR shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Friday, July 17th. Wall Street Zen upgraded shares of Jasper Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, July 25th. TD Cowen lowered shares of Jasper Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. Finally, Royal Bank Of Canada set a $3.00 price objective on shares of Jasper Therapeutics and gave the company a “sector perform” rating in a report on Friday, May 15th.

Jasper Therapeutics Stock Performance

Shares of Jasper Therapeutics stock opened at $0.60 on Thursday. Jasper Therapeutics has a 52 week low of $0.32 and a 52 week high of $3.14. The stock has a 50 day moving average price of $0.60 and a two-hundred day moving average price of $0.97. The stock has a market capitalization of $16.80 million, a PE ratio of -0.19 and a beta of 3.07.

Jasper Therapeutics (NASDAQ:JSPR) last issued its earnings results on Thursday, May 14th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.08. Research analysts forecast that Jasper Therapeutics will post -1.67 EPS for the current year.

Hedge Funds Weigh In On Jasper Therapeutics

Large investors have recently added to or reduced their stakes in the business. Knott David M Jr boosted its stake in Jasper Therapeutics by 5.8% during the 4th quarter. Knott David M Jr now owns 181,389 shares of the company’s stock valued at $332,000 after purchasing an additional 10,000 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Jasper Therapeutics in the first quarter worth approximately $46,000. Engineers Gate Manager LP purchased a new stake in shares of Jasper Therapeutics in the second quarter worth approximately $78,000. Renaissance Technologies LLC lifted its holdings in shares of Jasper Therapeutics by 9.0% in the fourth quarter. Renaissance Technologies LLC now owns 227,183 shares of the company’s stock valued at $416,000 after purchasing an additional 18,683 shares in the last quarter. Finally, Panagora Asset Management Inc. bought a new position in shares of Jasper Therapeutics in the fourth quarter valued at approximately $35,000. Institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.